Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients


16 Sep 2021


ePoster Display


Sergei Krasny


Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689


S. Krasny1, S. Polyakov2, E. Zhavrid3, A. Khorau4, Y. Baranau5, S. Kozlovskaya6, O. Sergeeva3, K. Zharkova3, A.A. Sufianov7, V. Gabai8, A. Shneider9

Author affiliations

  • 1 Deputy Director For Research, N.N. Alexandrov National Cancer Center of Belarus, 223040 - Minsk/BY
  • 2 Director, N.N. Alexandrov National Cancer Center of Belarus, 223040 - Minsk/BY
  • 3 Chemotherapy Dept., N.N. Alexandrov National Cancer Center of Belarus, 223040 - Minsk/BY
  • 4 Reconstructive Plastic Surgery And Mammologic Oncology Unit, N.N. Alexandrov National Cancer Center of Belarus, 223040 - Minsk/BY
  • 5 Chemotherapy Department 1, Minsk City Clinical Oncologic Dispensary, 220089 - Minsk/BY
  • 6 Chemotherapy Dept., N.N. Alexandrov National Cancer Center of Belarus, 220040 - Minsk/BY
  • 7 Neurosurgery, Federal Center of Neurosurgery, 625032 - Tyumen/RU
  • 8 Vice President, CureLab Oncology, Inc., Boston/US
  • 9 Ceo, CureLab Oncology, Inc., Boston/US

Abstract 278P


CMF (Cyclophosphamide 600mg/m2 + Methotrexate 40mg/m2 + Fluorouracil 600mg/m2, IV, day 1 and 8, every 4 weeks) remains a chemotherapeutic modality effective for metastatic triple-negative breast cancer (mTNBC). A plasmid encoding p62/SQTM1 reduces chronic inflammation, changes the tumor microenvironment, and increases the number of tumor-infiltrating lymphocytes. Dosing of the plasmid preserved the lives of 10 out of 11 dogs with breast cancer. In a human phase I/IIa trial, it demonstrated an excellent safety profile and limited cancer progression.


This ongoing prospective randomized clinical study tests an adjuvant potency of p62-plasmid administered in combination with CMF in mTNBC patients. In this first interim report, we analyzed the treatment result of 11 mTNBC patients randomized into groups receiving CMF alone (n=5) or CMF in combination with the p62-plasmid (n=6). The plasmid was injected at 2.5 mg weekly IM. Efficacy was assessed in accordance with the RECIST 1.1 criteria. Progression free survival (PFS) was assessed from the date of randomization until the first indication of disease progression (to date no deaths in either group).


After multiple courses of CMF plus p62, two patients (33,3%) demonstrated complete response (CR) of tumor lesions, and 3 patients (50.0%) had a partial response (PR). To date, no patient in the p62 group has progressed. Afterward, both CR patients underwent surgery. One patient had pCR (pathologic complete response) and another – pCR in tumor and 1 metastasis (from 20 removed lymph nodes). In the CMF - only group, transient PR was observed in 2 patients (40,0%). The median of observation is 14.0 and 11.0 weeks for the p62 plus CMF and CMF-only group respectively. PFS difference between the p62 plus CMF and CMF only groups was statistically significant (р=0.028). No Grade 3-4 toxicities were observed according to CT CAE v.4.0.


A plasmid p62-encoding may be a safe and effective to CMF chemotherapy in mTNBC.

Clinical trial identification

Editorial acknowledgement

The authors would like to thank Dr. Robert Devlin and Mr. Aaron Shneider for editorial assistance.

Legal entity responsible for the study

N.N. Alexandrov National Cancer Center of Belarus.


Has not received any funding.


V. Gabai, A. Shneider: Financial Interests, Institutional, Full or part-time Employment: CureLab Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.